Testing for the EGFR Mutation
Comprehensive biomarker testing can determine whether an EGFR lung cancer mutation or another lung cancer mutation is present. If you receive a lung cancer diagnosis, the very first thing you should do is make sure your doctors have ordered comprehensive biomarker testing done on your lung cancer tumor. In addition to having this key testing done, you should have the results before starting any treatment, including chemo and/or immunotherapy.
The comprehensive biomarker testing will involve a biopsy of your lung cancer. This biopsy removes tissue. The tissue is then tested for its genetic makeup, or biomarkers. In most cases, biomarker testing can use the same tissue that was obtained during the original biopsy. (The biopsy which was used to diagnosing the lung cancer.)
Remember These Important Points to Biomarker Testing
A blood biopsy is especially effective in detecting the presence of EGFR NSCLC. This biopsy can be performed before comprehensive biomarker testing. If the blood biopsy shows positive for an EGFR mutation, then the patient can be started on an EGFR inhibitor.
But, in all other instances, it is important to have comprehensive biomarker testing.